Skip to main content

Aerovate Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

JBIO$15.60+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized**.**

​
​AEROVATE THERAPEUTICS, INC.
​​​
Date: March 25, 2024​By:/s/ Timothy P. Noyes
​​​Timothy P. Noyes
​​​Chief Executive Officer

Each person whose individual signature appears below hereby authorizes and appoints Timothy P. Noyes and George A. Eldridge, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on March 25, 2024.

NameTitleDate
​​​​​​
/s/ Timothy P. Noyes​Chief Executive Officer and Director​March 25, 2024​
Timothy P. Noyes​(Principal Executive Officer)​​
​​​​​​
/s/ George A. Eldridge​Chief Financial Officer​March 25, 2024​
George A. Eldridge​(Principal Financial Officer and Principal​​
​​Accounting Officer)​​​
​​​​​​
/s/ Habib Dable​Director​March 25, 2024​
Habib Dable​​​​​
​​​​​​
/s/ Allison Dorval​Director​March 25, 2024​
Allison Dorval​​​
​​​​​​
/s/ David Grayzel, M.D​Director​March 25, 2024​
David Grayzel, M.D​​​
​​​​​​
/s/ Mark Iwicki​Director​March 25, 2024​
Mark Iwicki​​​
​​​​​​
/s/ Maha Katabi, Ph.D.​Director​March 25, 2024​
Maha Katabi, Ph. D.​​​
​​​​​​
/s/ Joshua Resnick, M.D.​Director​March 25, 2024​
Joshua Resnick, M.D.​​​
​​​​​​
/s/ Donald J. Santel​Director​March 25, 2024​
Donald J. Santel​​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.